TearClear announces initation of TC-002 Latanoprost Ophthalmic Solution Phase 3 trial
TearClear, a late clinical stage ophthalmic pharmaceutical company, is pleased to announce the TC-002 Phase 3 trial has been successfully initiated. TearClear’s Phase 3 trial (CLEAR Study) is a prospective, double-masked, randomized, multi-center, active-controlled, parallel-group, 3-month study assessing the safety and ocular hypotensive efficacy of TC-002 Ophthalmic Solution (TearClear Preservative-Free Latanoprost Ophthalmic Solution 0.005%) compared to marketed Latanoprost Ophthalmic Solution 0.005%.
TearClear has developed a novel investigational platform through which topical ophthalmic solutions are preserved in a patient-friendly multi-dose bottle but are delivered to the ocular surface as preservative-free.
Approximately 30%-40% of patients who rely on preserved, chronic glaucoma therapies show signs of moderate to severe Ocular Surface Disease (OSD)1. Studies have suggested that removal of preservatives may be beneficial for the ocular health of such patients. To date, options for these patients have been less than adequate. Thomas Samuelson, MD at Minnesota Eye Consultants commented, “Up until now, the preservative-free options available to patients are accompanied with compromises related to cost and ease of use. TearClear’s approach offers patients the best of both worlds, where preservatives remain in the bottle but kept off the ocular surface.”
Read the full press release here.